Cardiometabolic risk factors and their relationship with the interleukin-6 receptor gene polymorphism (rs2228145) in patients with hypertrophic cardiomyopathy

Aim. To analyze associations of interleukin-6 receptor gene (IL6R) polymorphism (rs2228145) with the clinical course characteristics of hypertrophic cardiomyopathy (HCM) in groups of patients with various cardiometabolic risk factors

Material and methods. The sample consisted of 123 patients with HCM. The age  of the included patients ranged from 18 to 91 years (59 [41; 66.5]), of whom 59 were men, 64 — women. Two age groups were identified: the first group included patients from 18 to 44 years old, the second — 45 years and older. The control group consisted of 200 people without cardiovascular diseases and other severe comorbidities.

For genetic testing, DNA was isolated from peripheral blood lymphocytes. Genotyping of the IL6R gene polymorphism (rs2228145) was carried out by realtime polymerase chain reaction.

Results. A significant prevalence of CC genotype of the IL6R gene polymorphism (rs2228145) was revealed in patients aged ³45 years compared with the control group, which occurred in 14,1% and 3,0% of cases, respectively (CC:AC+AA, odds ratio (OR), 0,885, 95% confidence interval (CI), 1,051-0,691, p=0,006), and insignificant prevalence of C allele in this group, which does not reach the level of significance (A:C, OR, 0,870, 95% CI, 0,427-1,02, p=0,06). The prevalence of CC genotype (15,1% vs 3,0%) and C allele (39,0% vs 29,0%) was revealed in patients with HCM in combination with hypertension (HTN) compared with the control group (CC:AS+AA, OR=0,174, 95% CI, 0,047-0,650), p=0,004); (A:C, OR=0,638, 95% CI, 0,406-1,002), p=0,05).

Conclusion. The relationship between the IL6R gene polymorphism (rs2228145) and HTN in patients with HCM was confirmed. The presence of CC genotype and C allele of the rs2228145 IL6R gene polymorphism is significantly more common in patients with HCM with the disease onset ³45 years of age. The presence of CC genotype and C allele of the IL6R gene polymorphism (rs2228145) is associated with HTN in patients with HCM.

1. Elliot P, Zamorano JL, Anastasakis A, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: The task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733-79. doi:10.1093/eurheartj/ehu284.

2. Finocchiaro G, Magavern E, Sinagra G, et al. Impact of demographic features, lifestyle, and comorbidities on the clinical expression of hypertrophic cardiomyopathy. J Am Heart Assoc. 2017;6(12):e007161. doi:10.1161/JAHA.117.007161.

3. Maron BJ, Rowin EJ, Casey SA, et al. Risk stratification and outcome of patients with hypertrophic cardiomyopathy ≥60 years of age. Circulation. 2013;127(5):585-93. doi:10.1161/CIRCULATIONAHA.112.136085.

4. Kaplunova VYu, Shakaryants GA, Kozhevnikova MV, et al. Hypertrophic Cardiomyopathy and Ischemic Heart Disease. Variants of Combination Pathology. Kardiologiia. 2017;57(12):16-24. (In Russ.). doi:10.18087/cardio.2017.12.10062.

5. Olivotto I, Maron BJ, Tomberli B, et al. Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013;62(5):449-57. doi:10.1016/j.jacc.2013.03.062.

6. Topol EJ, Traill TA, Fortuin NJ. Hypertensive Hypertrophic Cardiomyopathy of the Elderly. N Engl J Med. 1985;312(5):277-83. doi:10.1056/NEJM198501313120504.

7. Karam R, Lever HM, Healy BP. Hypertensive hypertrophic cardiomyopathy or hypertrophic cardiomyopathy with hypertension?: A study of 78 patients. J Am Coll Cardiol. 1989;13(3):580-4. doi:10.1016/0735-1097(89)90596-2.

8. Shimizu M, Sugihara N, Sffimizu K, et al. Asymmetrical septal hypertrophy in patients with hypertension: A type of hypertensive left ventricular hypertrophy or hypertrophic cardiomyopathy combined with hypertension? Clin Cardiol. 1993;16(1):41-6. doi:10.1002/clc.4960160110.

9. Canepa M, Sorensen LL, Pozios I, et al. Comparison of clinical presentation, left ventricular morphology, hemodynamics, and exercise tolerance in obese versus nonobese patients with hypertrophic cardiomyopathy. Am J Cardiol. 2013;112(8):1182-9. doi:10.1016/j.amjcard.2013.05.070.

10. Ommen SR, Lopez-Jimenez F. Obesity and hypertrophic cardiomyopathy: Chickens, eggs, and causality: Clinical skills remain the key to caring for patients. J Am Coll Cardiol. 2013;62(5):458-9. doi:10.1016/j.jacc.2013.03.063.

11. Ross R. Atherosclerosis — An inflammatory disease. New England Journal of Medicine. 1999;340(2):115-26. doi:10.1056/NEJM199901143400207.

12. Vostrikova NV, Fyodorov DV, Klimova EE, Bishevsky KM. Prognostic importance of inflammation markers (c-reactive protein and interleukin-6) in patients with arterial hypertension. Bulletin of Medical Science. 2019;1(13):44-6. (In Russ.). doi:10.31684/25418475.2019.1(13).44-46.

13. Harrison DG, Guzik TJ, Lob HE, et al. Inflammation, immunity, and hypertension. Hypertension. 2011;57(2):132-40. doi:10.1161/HYPERTENSIONAHA.110.163576.

14. Bautista LE, Vera LM, Arenas IA, et al. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-α) and essential hypertension. J Hum Hypertens. 2005;19(2):149-54. doi:10.1038/sj.jhh.1001785.

15. Vostrikova NV, Fyodorov DV, Mamayev AN, et al. Markers of inflammatory reaction (c-reactive protein and interleukin-6) in arterial hypertension. Sibirskii meditsinskii jurnal (Tomsk). 2009;24(4-1):33-4. (In Russ.)

16. Osipova OA, Suyazova SB, Vlasenko MA, et al. Role of proinflammatory cytokines in chronic heart failure. Rossiiskii mediko-biologicheskii vestnik imeni akademika I. P. Pavlova. 2013;21(2):130-5. (In Russ.). doi:10.17816/PAVLOVJ20132130-135.

17. Kosmala W, Derzhko R, Przewlocka-Kosmala M, et al. Plasma levels of TNF-α, IL-6, and IL-10 and their relationship with left ventricular diastolic function in patients with stable angina pectoris and preserved left ventricular systolic performance. Coron Artery Dis. 2008;19(6):375-82. doi:10.1097/MCA.0b013e3282fc617c.

18. Hedayat M, Mahmoudi MJ, Rose NR, et al. Proinflammatory cytokines in heart failure: Double-edged swords. Heart Failure Reviews. 2010;15:543-62. doi:10.1007/s10741-0109168-4.

19. Gabriele P, Zhi Fang S, Tonny DT, et al. Activation of the cardiac interleukin-6 system in advanced heart failure. Eur J Heart Fail. 2001;3(4):415-21. doi:10.1016/S13889842(01)00137-4.

20. Popkova TV, Novikov DS, Nasonov EL. Interleykin 6 i serdechno-sosudistaya patologiya pri revmatoidnom artrite. Rheumatology Science and Practice. 2011;49(4):64-72. (In Russ.). doi:10.14412/1995-4484-2011-63.

21. Buzás K, Megyeri K, Hõgye M, et al. Comparative study of the roles of cytokines and apoptosis in dilated and hypertrophic cardiomyopathies. Eur Cytokine Netw. 2004;15(1):53-9.

22. Kishimoto T, Akira S, Narazaki M, et al. Interleukin-6 family of cytokines and gp130. Blood. 1995;86(4):1243-54. doi:10.1182/blood.V86.4.1243.bloodjournal8641243.

23. Kishimoto T, Taga T, Akira S. Cytokine signal transduction. Cell. 1994;76:253-62. doi:10.1016/0092-8674(94)90333-6.

24. Hirota H, Yoshida K, Kishimoto T, et al. Continuous activation of gp130, a signaltransducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci U S A. 1995;92(11):4862-6. doi:10.1073/pnas.92.11.4862.

25. Chen Z, Qian Q, Tang C, et al. Association of two variants in the interleukin-6 receptor gene and premature coronary heart disease in a Chinese Han population. Mol Biol Rep. 2013;40(2):1021-6. doi:10.1007/s11033-012-2143-5.

26. Zhou J, Chen X, Ye H, et al. An Association Study between Genetic Polymorphism in the Interleukin-6 Receptor Gene and Coronary Heart Disease. Biomed Res Int. 2014;504727. doi:10.1155/2014/504727.

27. Mitrokhin V, Nikitin A, Brovkina O, et al. Association between interleukin-6/6R gene polymorphisms and coronary artery disease in Russian population: Influence of interleukin6/6R gene polymorphisms on inflammatory markers. J Inflamm Res. 2017;10:151-60. doi:10.2147/JIR.S141682.

28. Esteve E, Villuendas G, Mallolas J, et al. Polymorphisms in the interleukin-6 receptor gene are associated with body mass index and with characteristics of the metabolic syndrome. Clin Endocrinol (Oxf). 2006;65(1):88-91. doi:10.1111/j.1365-2265.2006.02553.x.

29. Jiang CQ, Lam TH, Liu B, et al. Interleukin-6 Receptor Gene Polymorphism Modulates Interleukin-6 Levels and the Metabolic Syndrome: GBCS-CVD. Obesity. 2010;18(10):196974. doi:10.1038/oby.2010.31.

30. Topchieva LV, Korneva VA, Kurbatova IV. The relationship of the carriership of allelic variations in rs2228145 (A>C) of the IL6R gene with the levels of VCAM1 and ICAM1 gene transcripts in patients with essential hypertension. Vavilovskii Zhurnal Genetiki i Selektsii. 2020;24(1):96-101. (In Russ.). doi:10.18699/VJ20.600.

31. Chu NF, Lin FH, Chin HC, et al. Association between interleukin-6 receptor gene variations and atherosclerotic lipid profiles among young adolescents in Taiwan. Lipids Health Dis. 2011;10:136. doi:10.1186/1476-511X-10-136.

32. Arguinano AA, Naderi E, Ndiaye NC, et al. IL6R haplotype rs4845625T/rs4537545C is a risk factor for simultaneously high CRP, LDL and ApoB levels. Genes Immun. 2017;18(3):163-9. doi:10.1038/gene.2017.16.

33. Wypasek E, Potaczek DP, Lamplmayr M, et al. Interleukin-6 receptor ASP358ALA gene polymorphism is associated with plasma C-reactive protein levels and severity of aortic valve stenosis. Clin Chem Lab Med. 2014;52(7):1049-56. doi:10.1515/cclm-2013-0606.

34. Abel ED, Litwin SE, Sweeney G. Cardiac remodeling in obesity. Physiological Reviews. 2008;88:389-419. doi:10.1152/physrev.00017.2007.

35. Poliakova AA, Gudkova AY, Krutikov AN, et al. Hypertrophic cardiomyopathy in the older age group: The effect of cardiometabolic risk factors and rs2290149 and rs10838692 of the MADD gene. Arter Hypertens. 2018;24(1):29-40. (In Russ.). doi:10.18705/1607419X-2018-24-1-29-40.

36. Poliakova AA, Baranova EI, Semernin EN, et al. Gender differences of clinical manifestation and cardiac remodeling in idiopathic hypertrophic cardiomyopathy in elderly patients. Russ J Cardiol. 2018;154(2):13-8. (In Russ.). doi:10.15829/1560-4071-2018-2-13-18.

37. Ingles J, Burns C, Bagnall RD, et al. Nonfamilial Hypertrophic Cardiomyopathy: Prevalence, Natural History, and Clinical Implications. Circ Cardiovasc Genet. 2017;10(2):e001620. doi:10.1161/CIRCGENETICS.116.001620.

38. Maron BJ, Piccininno M, Casey SA, et al. Relation of extreme left ventricular hypertrophy to age in hypertrophic cardiomyopathy. Am J Cardiol. 2003;91(5):626-8. doi:10.1016/S0002-9149(02)03326-X.

39. Gudkova AYa, Davidova VG, Bezhanishvili TG, et al. Characterisation of circulating microRNA-21 levels in patients with hypertrophic cardiomyopathy. Therapeutic Archive. 2020;92(4):51-6. (In Russ.). doi:10.26442/00403660.2020.04.000272.

40. Spirito P, Maron BJ. Relation Between Extent of Left Ventricular Hypertrophy Hypertrophic Cardiomyopathy. JACC. 1990;15(4):808-13. doi:10.1016/0735-1097(90)90278-W.

41. Wolf J, Rose-John S, Garbers C. Interleukin-6 and its receptors: a highly regulated and dynamic system. Cytokine. 2014;70:11-20. doi:10.1016/j.cyto.2014.05.024.